When can dual antiplatelet therapy be stopped after percutaneous coronary intervention based on stent type, clinical presentation, and bleeding risk?

When to Stop Dual Antiplatelet Therapy After PCI

For acute coronary syndrome (ACS) patients, discontinue the P2Y12 inhibitor at 12 months and continue aspirin indefinitely; for stable coronary artery disease, discontinue the P2Y12 inhibitor at 6 months and continue aspirin indefinitely. 1, 2

Standard DAPT Duration by Clinical Presentation

Acute Coronary Syndrome (NSTEMI/STEMI)

• Default duration: 12 months of DAPT (aspirin plus P2Y12 inhibitor), regardless of whether the patient received medical therapy alone, PCI, or CABG 1, 2
• After 12 months, stop the P2Y12 inhibitor and continue aspirin 75-100 mg daily indefinitely 1, 2
• The 12-month duration applies irrespective of stent type (bare-metal stent vs. drug-eluting stent) 1

Stable Coronary Artery Disease

• Duration: 1-6 months of DAPT depending on bleeding risk, with most patients stopping at 6 months 1, 2
• After completing DAPT, continue aspirin 75-100 mg daily indefinitely 1, 2
• Stent type (BMS vs. DES) should not dictate DAPT duration; newer-generation DES no longer justify prolonged DAPT 1

Modified Duration Based on Bleeding Risk

High Bleeding Risk Patients

• ACS patients: Shorten DAPT to 6 months, then continue aspirin monotherapy 1, 2
• Stable CAD patients: Shorten DAPT to 1-3 months, then continue aspirin monotherapy 1, 2
• High bleeding risk is defined by factors such as age >75 years, prior bleeding history, chronic kidney disease, or need for oral anticoagulation 1

Very High Bleeding Risk (Life-Threatening Bleeding)

• Absolute minimum: 1 month of DAPT even in extreme bleeding scenarios 2
• If life-threatening bleeding occurs after 1 month post-PCI, stop the P2Y12 inhibitor immediately but continue aspirin to prevent catastrophic stent thrombosis (mortality 20-40% if both agents stopped) 2
• Never stop both aspirin and P2Y12 inhibitor simultaneously except in extremis 2

Low Bleeding Risk with High Ischemic Risk

• ACS patients who tolerate 12 months of DAPT without bleeding: Consider extending beyond 12 months 1, 2
• Factors favoring prolonged DAPT include prior stent thrombosis, complex PCI (bifurcation requiring two stents, total stent length >60mm, multiple lesions), or left main disease 1, 2

Special Populations

Patients Requiring Oral Anticoagulation (Atrial Fibrillation, Mechanical Valve)

• Triple therapy (DAPT + anticoagulation) should be limited to maximum 6 months or omitted after hospital discharge 1, 2
• Stop aspirin first at 1-3 months, continue P2Y12 inhibitor (preferably clopidogrel, not ticagrelor or prasugrel) plus anticoagulation 1
• After completing dual therapy (P2Y12 inhibitor + anticoagulation), stop the P2Y12 inhibitor at 12 months and continue anticoagulation alone 1
• Triple therapy increases bleeding risk 2-3 fold compared to anticoagulation alone 1, 2

Left Main Disease

• Minimum 12 months of DAPT regardless of clinical presentation 2
• Strongly consider extending beyond 12 months if patient tolerates DAPT without bleeding, as left main PCI is inherently complex anatomy 2
• If shortened DAPT is necessary due to bleeding risk, mandatory proton pump inhibitor (PPI) therapy 2

Patients Requiring Non-Cardiac Surgery

• Wait at least 1 month after stent implantation before elective surgery requiring P2Y12 inhibitor discontinuation, if aspirin can be maintained perioperatively 1
• For urgent surgery within 30 days of DES placement, continue DAPT unless bleeding risk significantly outweighs stent thrombosis risk 3

Mandatory Reassessment Timepoints

Critical Decision Points

• At 6 months: Reassess all patients; high bleeding risk patients may stop P2Y12 inhibitor 2
• At 12 months: Mandatory reassessment for all patients; decision to continue or stop DAPT must be actively made 2
• Failing to reassess at 12 months is a critical error—do not allow patients to continue DAPT indefinitely by default 2

Immediate Reassessment Triggers

• Significant overt bleeding: Stop P2Y12 inhibitor immediately if >1 month post-PCI; continue aspirin 2
• Stroke or TIA on prasugrel: Discontinue prasugrel immediately (absolute contraindication) 2
• Planned major intracranial surgery: Requires multidisciplinary evaluation for temporary DAPT interruption 1, 2

P2Y12 Inhibitor Selection and Switching

Initial Selection

• ACS patients: Ticagrelor (180 mg load, 90 mg twice daily) or prasugrel (60 mg load, 10 mg daily) preferred over clopidogrel 1, 2
• Stable CAD patients: Clopidogrel (75 mg daily) is the default P2Y12 inhibitor 1
• Patients on oral anticoagulation: Clopidogrel only; do not use ticagrelor or prasugrel 1

De-escalation Strategy

• Switching from ticagrelor/prasugrel to clopidogrel may be considered for patients with bleeding events or high bleeding risk 1
• Recent evidence supports 3-month DAPT with high-potency P2Y12 inhibitor monotherapy (without aspirin) as superior to aspirin monotherapy in reducing net adverse clinical events 4

Bleeding Mitigation While on DAPT

Mandatory Measures

• Aspirin dose: 75-100 mg daily (not higher doses) 1
• Proton pump inhibitor (PPI) therapy for all patients on DAPT to reduce gastrointestinal bleeding 1, 2
• Radial artery access for PCI when possible to reduce access-site bleeding 1

Common Pitfalls to Avoid

• Do not use stent type to determine DAPT duration—base decisions on clinical presentation and bleeding risk, not whether BMS or DES was used 1
• Do not stop both antiplatelet agents simultaneously except in life-threatening bleeding where source cannot be controlled 2
• Do not assume stable disease permits early DAPT cessation—ACS patients retain elevated thrombotic risk for 6-12 months 2
• Do not restart potent P2Y12 inhibitors (ticagrelor/prasugrel) in patients with gastrointestinal bleeding history—use clopidogrel if P2Y12 inhibitor needed 2
• Do not continue DAPT beyond 12 months without active reassessment—this decision requires weighing ongoing ischemic vs. bleeding risk 2